Neuren reports positive top-line results from Phase II trial of trofinetide for Rett syndrome

Australian-based biopharmaceutical firm Neuren Pharmaceuticals has reported positive top-line results from the Phase II clinical trial of trofinetide to treat girls with Rett syndrome.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news